针对复发性clostridioides difficile感染的先进治疗方法:对vowst的FDA批准和影响的概述
Nityanand Jain1,2, Tungki Pratama Umar3, Anne-Fleur Fahner4,5
1Faculty of Medicine, Riga Stradinš University, Riga, Latvia.
Gut microbes
|July 11, 2023
概括
美国食品和药物管理局批准了Vowst,这是一种口服便微生物群移植 (FMT) 疗法,用于预防复发性Clostridioides difficile感染 (CDI). 这种新的治疗方法恢复了肠道微生物群,以对抗C. difficile.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
背景情况:
- 困难菌感染 (CDI) 是医疗保健相关感染的重要原因之一.
- 高复发率使CDI治疗复杂化,需要先进的治疗策略.
- 目前的指导方针建议在初始发作时使用菲达克索米辛,在复发病例中使用便微生物群移植 (FMT).
研究的目的:
- 探索最近FDA批准Vowst,一种口服FMT药物用于预防复发性CDI.
- 讨论Vowst在恢复肠道微生物群和限制C. difficile发芽的作用机制.
- 检查围绕Vowst使用的含义,不确定性和未来考虑.
主要方法:
- 对支持Vowst疗效的临床试验数据的审查.
- 对Vowst.的FDA批准过程的分析.
- 讨论批准后考虑因素,包括药物监测和成本.
主要成果:
- 活体便微生物体子的口服配方Vowst已经获得FDA的批准.
- 该疗法通过恢复肠道微生物群,抑制C. difficile子发芽和促进微生物组修复来起作用.
- 临床试验证明了Vowst对复发性CDI的预防潜力.
结论:
- 沃斯特代表了预防复发性CDI的重大进展.
- 需要进一步的研究和药监测,才能充分了解其长期的疗效和安全性.
- 批准强调了微生物组治疗在胃肠道学中日益增长的作用.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
198
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
198
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
160
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
160
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175


